

Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

July 2024

The logo for PHARMAC, featuring the word "PHARMAC" in a bold, uppercase, sans-serif font, with "TE PĀTAKA WHAIORANGA" in a smaller, uppercase, sans-serif font below it. The logo is centered within a white circle that overlaps a background of stylized, concentric, wavy lines in shades of gray and white.

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

Summary of decisions effective 1 July 2024	3
Section H changes to Part II	9
Index	25

Summary of decisions

EFFECTIVE 1 JULY 2024

- Abacavir sulphate oral liq 20 mg per ml – new listing
- Adalimumab (Humira – alternative brand) (HumiraPen) inj 40 mg per 0.4 ml prefilled pen – new Pharmacode listing
- Adenosine (Adenocor) inj 3 mg per ml, 2 ml vial – to be delisted from 1 December 2024
- Adenosine inj 3 mg per ml, 2 ml vial (Adsine) and inj 3 mg per ml, 10 ml vial (Adenosine Baxter) – new listing
- Adrenaline (DBL Adrenaline) inj 1,000, 1 ml ampoule – price increase
- Amikacin (DBL Amikacin) inj 250 mg per ml, 2 ml vial – price decrease and addition of PSS
- Amisulpride (Sulprix) tab 100 mg, 200 mg and 400 mg – price decrease and addition of PSS
- Amoxicillin with clavulanic acid (Augmentin) grans for oral liq 25 mg with clavulanic acid 6.25 mg per ml, 100 ml – price increase
- Amoxicillin with clavulanic acid (Cerobact) inj 1,000 mg with clavulanic acid 200 mg vial – new listing
- Aripiprazole (Abilify Maintena) inj 300 mg vial and 400 mg vial – new listing
- Atorvastatin (Lorstat) tab 10 mg, 20 mg, 40 mg and 80 mg – price decrease and addition of PSS
- Bacillus calmette-guerin vaccine (BCG Vaccine AJV) – amended brand name and addition of PSS
- Baclofen (Pacifen) tab 10 mg – price decrease and addition of PSS
- Bedaquiline (Sirturo) tab 100 mg, 188 tab pack – revoke delisting
- Betamethasone dipropionate with calcipotriol (Daivobet) gel 500 mcg with calcipotriol 50 mcg per g, 60 g – price increase and addition of PSS
- Betamethasone dipropionate with calcipotriol (Daivobet) oint 500 mcg with calcipotriol 50 mcg per g, 30 g – price decrease and addition of PSS
- Brimonidine tartrate with timolol maleate (Combigan) eye drops 0.2% with timolol 0.5%, 5 ml – amended chemical name, new listing and addition of PSS
- Brinzolamide (Azopt) eye drops 1%, 5 ml – price decrease and addition of PSS
- Buspirone (Buspirone Viartis) tab 10 mg – addition of PSS
- Buspirone (Buspirone Viartis) tab 5 mg – price decrease and addition of PSS
- Carbamazepine (Tegretol AU) tab 200 mg – new listing
- Carboplatin (Carboplatin Accord) inj 10 mg per ml, 45 ml vial – new listing and addition of PSS
- Carboplatin (Carboplatin Ebewe) inj 10 mg per ml, 45 ml vial – to be delisted from 1 December 2024

Summary of decisions – effective 1 July 2024 (continued)

- Cefepime (Cefepime-AFT) inj 1 g vial and 2 g vial – new listing and addition of PSS
- Cefepime (Cefepime-Kabi) inj 1 g vial and 2 g vial – to be delisted 1 December 2024
- Cinacalcet (Cinacalcet Devatis) tab 30 mg and 60 mg – price decrease and addition of PSS
- Ciprofloxacin (Cipflox) tab 750 mg – to be delisted from 1 December 2024
- Ciprofloxacin (Ipsa-Ciprofloxacin) tab 750 mg – new listing and addition of PSS
- Cisplatin (Cisplatin Accord) inj 1 mg per ml, 100 ml vial – new listing and addition of PSS
- Cisplatin (DBL Cisplatin) inj 1 mg per ml, 100 ml vial – to be delisted from 1 December 2024
- Clindamycin (Dalacin C) cap 150 mg – price decrease and addition of PSS
- Covid-19 vaccine (Comirnaty Omicron (XBB.1.5)) inj 10 mcg raxtozinameran per 0.3 ml, 0.48 ml vial; paediatric vaccine, light blue cap – new listing
- Covid-19 vaccine (Comirnaty Omicron (XBB.1.5)) inj 3 mcg raxtozinameran per 0.2 ml, 0.4 ml vial; infant vaccine, maroon cap – new listing
- Covid-19 vaccine (Comirnaty Omicron (XBB.1.5)) inj 30 mcg raxtozinameran per 0.3 ml, 2.25 ml vial; adult vaccine, dark grey cap – new listing
- Covid-19 vaccine (Comirnaty Omicron (XBB.1.5)) inj 30 mcg raxtozinameran per 0.3 ml, 0.48 ml vial; adult vaccine, light grey cap – new listing
- Cyclophosphamide (Cyclonex) tab 50 mg – addition of PSS
- Daunorubicin (Daunorubicin Zentiva) inj 20 mg vial – to be delisted from 1 July 2024
- Diabetic oral feed 1 kcal/ml (Diasip (strawberry and vanilla)) liquid 4.9 g protein, 11.7 g carbohydrate, 3.8 g fat and 2 g fibre per 100 ml, 200 ml bottle – new listing
- Diphtheria, tetanus and pertussis vaccine (Boostrix) – amended presentation description and addition of PSS
- Diphtheria, tetanus, pertussis and polio vaccine (Infanrix IPV) – addition of PSS
- Diphtheria, tetanus, pertussis, polio, hepatitis b and haemophilus influenzae type B vaccine (Infanrix-hexa) – amended presentation description and addition of PSS
- Dobutamine (Dobutamine-hameln) inj 12.5 mg per ml, 20 ml ampoule – addition of PSS
- Eplerenone (Inspra) tab 25 mg – price decrease and addition of PSS
- Eplerenone (Inspra) tab 50 mg – addition of PSS
- Fentanyl (Fentanyl Sandoz) patch 12.5 mcg per hour, 25 mcg per hour, 50 mcg per hour, 75 mcg per hour and 100 mcg per hour – price decrease and addition of PSS
- Ferrous fumarate with folic acid (Ferro-F-Tabs) tab 310 mg (100 mg elemental) with folic acid 350 mcg – addition of PSS

Summary of decisions – effective 1 July 2024 (continued)

- Filgrastim (Nivestim) inj 300 mcg in 0.5 ml prefilled syringe and 480 mcg in 0.5 ml prefilled syringe – price decrease and addition of PSS
- Flumazenil (Flumazenil-Baxter) inj 0.1 mg per ml, 5 ml ampoule – new listing and addition of PSS
- Flumazenil (Hameln) inj 0.1 mg per ml, 5 ml ampoule – to be delisted from 1 December 2024
- Fluorouracil (Fluorouracil Accord) inj 50 mg per ml, 100 ml vial – price decrease and addition of PSS
- Fluorouracil (Fluorouracil Accord) inj 50 mg per ml, 20 ml vial – addition of PSS
- Fluorouracil sodium (Efudix) crm 5% – price decrease and addition of PSS
- Glycomacropeptide and amino acid contains some phenylalanine (Glytactin Bettermilk) powder (neutral), 15 g protein, 15 g carbohydrate, 4.5 g fat per 40 g sachet – amended brand name
- Glycomacropeptide and amino acid contains some phenylalanine (PKU Build 10, PKU Build 20 Chocolate, Raspberry Lemonade, Smooth, Vanilla and PKU Glytactin RTD 15) powder – amended presentation description
- Haemophilus influenzae type b vaccine (Act-HIB) inj 10 mcg vial with diluent syringe – new listing and addition of PSS
- Heparin sodium (Hospira) inj 1,000 iu per ml, 1 ml ampoule – price increase
- Heparin sodium (Pfizer) inj 1,000 iu per ml, 5 ml ampoule – price increase
- Heparinised saline (Pfizer) inj 10 iu per ml, 5 ml ampoule – price increase
- Hepatitis A vaccine (Havrix 1440) inj 1440 ELISA units in 1 ml syringe – amended brand name and addition of PSS
- Hepatitis A vaccine (Havrix Junior) inj 720 ELISA units in 0.5 ml syringe – addition of PSS
- Hepatitis B recombinant vaccine (Engerix-B) inj 10 mcg per 0.5 ml prefilled syringe and 20 mcg per 1 ml prefilled syringe – addition of PSS
- Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] (Gardasil) inj 270 mcg in 0.5 ml syringe – amended restriction criteria and addition of PSS
- Hydrocortisone (Solu-Cortef) inj 100 mg vial – price decrease and addition of PSS
- Ipratropium bromide (Ipratropium IVAX) nebuliser soln 250 mcg per ml, 2 ml ampoule – new listing
- Isotretinoin (Oratane) cap 5 mg, 10 mg and 20 mg – addition of PSS
- Ketamine (Ketalar) inj 100 mg per ml, 2 ml vial – price increase
- Letrozole (Letrole) tab 2.5 mg – price decrease and addition of PSS
- Linezolid (Linezolid Kabi) inj 2 mg per ml, 300 ml bottle – addition of PSS
- Linezolid (Zyvox) tab 600 mg – price decrease and addition of PSS

Summary of decisions – effective 1 July 2024 (continued)

- Lomustine (Medac) cap 40 mg – new listing
- Measles, mumps and rubella vaccine (Priorix) – addition of PSS
- Mebendazole (Vermox) tab 100 mg – price decrease and addition of PSS
- Medroxyprogesterone (Provera HD) tab 100 mg – price increase
- Medroxyprogesterone acetate (Provera) tab 2.5 mg, 5 mg and 10 mg – price increase
- Melatonin (Vigisom) tab modified-release 2 mg – price decrease and addition of PSS
- Meningococcal (A, C, Y and W-135) conjugate vaccine (MenQuadfi) inj 10 mcg of each meningococcal polysaccharide conjugated to a total of approximately 55 mcg of tetanus toxoid carrier per 0.5 ml vial – addition of PSS
- Meningococcal (A, C, Y and W-135) conjugate vaccine (Nimenrix) inj 5 mcg of each meningococcal polysaccharide conjugated to a total of approximately 44 mcg of tetanus toxoid carrier per 0.5 ml vial – new listing
- Meningococcal C conjugate vaccine (Neisvac-C) inj 10 mcg in 0.5 ml syringe – to be delisted from 1 December 2024
- Mercaptopurine (Xaluprine) oral suspension 20 mg per ml, 100 ml – new listing
- Methotrexate (Trexate) tab 2.5 mg and 10 mg – price decrease and addition of PSS
- Midostaurin (Rydapt) cap 25 mg – new listing
- Milrinone (Milrinone-Baxter) inj 1 mg per ml, 10 ml ampoule – price decrease and addition of PSS
- Nicotine (Habitrol (Fruit and Mint)) gum 2 mg and 4 mg – price increase
- Nicotine (Habitrol) lozenge 1 mg and 2 mg – price increase
- Nicotine (Habitrol) patch 7 mg per 24 hours, 14 mg per 24 hours, 21 mg per 24 hours – price increase
- Nitrofurantoin (Nifuran) tab 50 mg – addition of PSS
- Octreotide (Octreotide Depot Teva) inj 10 mg prefilled syringe and 20 mg prefilled syringe to be delisted from 1 December 2024 – to be delisted from 1 December 2024
- Octreotide (Sandostatin Lar) inj depot 10 mg prefilled syringe and 20 mg prefilled syringe – new listing and addition of PSS
- Octreotide (Sandostatin LAR) inj depot 30 mg prefilled syringe – addition of PSS
- Oestradiol (Lyllana) patch 25 mcg per day, 50 mcg per day, 75 mcg per day and 100 mcg per day – new listing
- Olanzapine (Zypine) tab 2.5 mg, 5 mg and 10 mg, 28 tab pack – delay delisting date

Summary of decisions – effective 1 July 2024 (continued)

- Oral feed 1.5 kcal/ml (Fortisip (banana, chocolate, strawberry and vanilla)) liquid 6 g protein, 18.4 g carbohydrate and 5.8 g fat per 100 ml, 200 ml bottle – new listing
- Oral feed with fibre 1.5 kcal/ml (Fortisip Multi Fibre (chocolate, strawberry and vanilla)) liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 2.3 g fibre per 100 ml, 200 ml bottle – new listing
- Oxycodone hydrochloride (Hameln) inj 10 mg per ml, 1 ml ampoule, inj 10 mg per ml, 2 ml ampoule, inj 50 mg per ml, 1 ml ampoule – price decrease and addition of PSS
- Oxycodone hydrochloride (Oxycodone Amneal) tab immediate-release 5 mg, 10 mg and 20 mg – new listing
- Oxycodone hydrochloride (Oxycodone Sandoz) tab controlled-release 5 mg, 10 mg and 20 mg – price decrease and addition of PSS
- Oxycodone hydrochloride (Oxycodone Sandoz) tab controlled-release 40 mg – price increase and addition of PSS
- Oxycodone hydrochloride (Oxycodone Sandoz) tab controlled-released 80 mg – addition of PSS
- Palbociclib (Ibrance) tab 75 mg, 100 mg and 125 mg – amended restriction criteria
- Parecoxib (Dynastat) inj 40 mg vial – price decrease and addition of PSS
- Perindopril (Coversyl) tab 2 mg – price increase and addition of PSS
- Perindopril (Coversyl) tab 4 mg and 8 mg – price decrease and addition of PSS
- Pioglitazone (Vexazone) tab 15 mg, 30 mg and 45 mg – price decrease and addition of PSS
- Pneumococcal (PCV13) conjugate vaccine (Prevenar 13) inj – addition of PSS
- Pneumococcal (PPV23) polysaccharide vaccine (Pneumovax 23) inj – addition of PSS
- Poliomyelitis vaccines (IPOL) inj 80 D-antigen units in 0.5 ml syringe – addition of PSS
- Prednisolone (Redipred) oral liq 5 mg per ml, 30 ml – addition of PSS
- Prednisolone sodium phosphate (Minims Prednisolone) eye drops 0.5%, single dose (preservative free), 20 dose – price increase
- Ribociclib (Kisqali) tab 200 mg – new listing
- Rifaximin (Xifaxan) tab 550 mg – addition of PSS
- Rotavirus oral vaccine (Rotarix) oral susp live attenuated human rotavirus 1,000,000 CCID50 per dose, prefilled oral applicator – addition of PSS
- Salbutamol (Ventolin) aerosol inhaler, 100 mcg per dose, 200 dose – price increase
- Salbutamol with ipratropium bromide (Duolin Cipla) nebuliser soln 2.5 mg with ipratropium bromide 0.5 mg per 2.5 ml – new listing
- Sildenafil (Vedafil) tab 100 mg – price increase and addition of PSS

Summary of decisions – effective 1 July 2024 (continued)

- Sildenafil (Vedafil) tab 25 mg and 50 mg – price decrease and addition of PSS
- Sodium hyaluronate [hyaluronic acid] (Hilo-Fresh) eye drops 1 mg per ml, 10 ml – price decrease and addition of PSS
- Sugammadex (Sugammadex BNM) inj 100 mg per ml, 2 ml vial and 5 ml vial – price decrease and addition of PSS
- Sulfadiazine silver (Ascend) crm 1%, 50 g – new listing
- Sulfadiazine sodium (e.g.Sulfadiazine-Heyl; Wockhardt) tab 500 mg – new example brand listing
- Ticagrelor (Ticagrelor Sandoz) tab 90 mg – price decrease and addition of PSS
- Tobramycin (Tobramycin (Viatris)) inj 40 mg per ml, 2 ml vial – price decrease and addition of PSS
- Travoprost (Travatan) eye drops 0.004%, 2.5 ml – price decrease and addition of PSS
- Trimethoprim with sulphamethoxazole [Co-trimoxazole] (Deprim) oral liq 8 mg with sulphamethoxazole 40 mg per ml, 100 ml – price increase
- Tuberculin PPD [Mantoux] text (Tubersol) inj 5 TU per 0.1 ml, 1 ml vial – addition of PSS
- Varicella vaccine [chickenpox vaccine] (Varilrix) inj 2000 PFU prefilled syringe, 10 inj pack – new listing and addition of PSS
- Varicella zoster vaccine [shingles vaccine] (Shingrix) inj 50 mcg per 0.5 ml vial plus vial – amended restriction criteria
- Zoledronic acid (Zoledronic acid Viatris) inj 4 mg per 5 ml, vial – price decrease and addition of PSS

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Section H changes to Part II

Effective 1 July 2024

ALIMENTARY TRACT AND METABOLISM

9	RIFAXIMIN (addition of PSS) → Tab 550 mg – 5% DV Dec-24 to 2027	625.00	56	Xifaxan
11	PIOGLITAZONE (↓ price and addition of PSS) Tab 15 mg – 5% DV Dec-24 to 2027	6.15	90	Vexazone
	Tab 30 mg – 5% DV Dec-24 to 2027	7.25	90	Vexazone
	Tab 45 mg – 5% DV Dec-24 to 2027	12.00	90	Vexazone
22	FERROUS FUMARATE WITH FOLIC ACID (addition of PSS) Tab 310 mg (100 mg elemental) with folic acid 350 mcg – 5% DV Dec-24 to 2027	5.98	100	Ferro-F-Tabs

BLOOD AND BLOOD FORMING ORGANS

36	TICAGRELOR (↓ price and addition of PSS) → Tab 90 mg – 5% DV Dec-24 to 2027	20.35	56	Ticagrelor Sandoz
38	FILGRASTIM (↓ price and addition of PSS) → Inj 300 mcg in 0.5 ml prefilled syringe – 5% DV Dec-24 to 2027	86.60	10	Nivestim
	→ Inj 480 mcg in 0.5 ml prefilled syringe – 5% DV Dec-24 to 2027	133.72	10	Nivestim

CARDIOVASCULAR SYSTEM

35	HEPARIN SODIUM (↑ price) Inj 1,000 iu per ml, 5 ml ampoule	127.44	50	Pfizer
	Inj 1,000 iu per ml, 1 ml ampoule	362.98	50	Hospira
35	HEPARINISED SALINE (↑ price) Inj 10 iu per ml, 5 ml ampoule	96.91	50	Pfizer
42	PERINDOPRIL (↑ price and addition of PSS) Tab 2 mg – 5% DV Dec-24 to 2027	1.79	30	Coversyl
42	PERINDOPRIL (↓ price and addition of PSS) Tab 4 mg – 5% DV Dec-24 to 2027	2.44	30	Coversyl
	Tab 8 mg – 5% DV Dec-24 to 2027	3.94	30	Coversyl
44	ADENOSINE (new listing and addition of PSS) Inj 3 mg per ml, 2 ml vial – 5% DV Dec-24 to 2027	34.50	5	Adsine
	→ Inj 3 mg per ml, 10 ml vial – 5% DV Dec-24 to 2027	100.00	5	Adenosine Baxter
	Note – Adenocor inj 3 mg per ml, 2 ml vial to be delisted from 1 December 2024			
48	EPLERENONE (↓ price and addition of PSS) → Tab 25 mg – 5% DV Dec-24 to 2027	15.84	30	Inspra

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2024 (continued)

48	EPLERENONE (addition of PSS) → Tab 50 mg – 5% DV Dec-24 to 2027	25.00	30	Inspra
49	ATORVASTATIN (↓ price and addition of PSS) Tab 10 mg – 5% DV Dec-24 to 2027	5.16	500	Lorstat
	Tab 20 mg – 5% DV Dec-24 to 2027	8.12	500	Lorstat
	Tab 40 mg – 5% DV Dec-24 to 2027	13.79	500	Lorstat
	Tab 80 mg – 5% DV Dec-24 to 2027	25.39	500	Lorstat
52	ADRENALINE (↑ price) Inj 1 in 1,000, 1 ml ampoule	13.27	1	DBL Adrenaline
52	DOBUTAMINE (addition of PSS) Inj 12.5 mg per ml, 20 ml ampoule – 5% DV Dec-24 to 2027	61.13	5	Dobutamine-hameln
53	MILRINONE (↓ price and addition of PSS) Inj 1 mg per ml, 10 ml ampoule – 5% DV Dec-24 to 2027	68.00	10	Milrinone-Baxter
58	SILDENAFIL (↓ price and addition of PSS) → Tab 25 mg – 5% DV Dec-24 to 2027	0.72	4	Vedafil
	→ Tab 50 mg – 5% DV Dec-24 to 2027	1.45	4	Vedafil
58	SILDENAFIL (↑ price and addition of PSS) → Tab 100 mg – 5% DV Dec-24 to 2027	11.22	12	Vedafil

DERMATOLOGICALS

65	SULFADIAZINE SILVER (new listing) Crm 1%	15.44	50 g	Ascend
66	ISOTRETINOIN (addition of PSS) Cap 5 mg – 5% DV Dec-24 to 2027	11.26	60	Oratane
	Cap 10 mg – 5% DV Dec-24 to 2027	18.75	120	Oratane
	Cap 20 mg – 5% DV Dec-24 to 2027	26.73	120	Oratane
69	BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL (↑ price and addition of PSS) Gel 500 mcg with calcipotriol 50 mcg per g – 5% DV Dec-24 to 2027	40.92	60 g	Daivobet
69	BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL (↓ price and addition of PSS) Oint 500 mcg with calcipotriol 50 mcg per g – 5% DV Dec-24 to 2027	14.31	30 g	Daivobet
70	FLUOROURACIL SODIUM (↓ price and addition of PSS) Crm 5% – 5% DV Dec-24 to 2027	5.56	20 g	Efudix

HORMONE PREPARATIONS

76	CINACALCET (↓ price and addition of PSS) → Tab 30 mg – 5% DV Dec-24 to 2027	25.24	28	Cinacalcet Devatis
	→ Tab 60 mg – 5% DV Dec-24 to 2027	50.47	28	Cinacalcet Devatis

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2024 (continued)

77	ZOLEDRONIC ACID (↓ price and addition of PSS) Inj 4 mg per 5 ml, vial – 5% DV Dec-24 to 2027	15.65	1	Zoledronic acid <i>Viatriis</i>
78	HYDROCORTISONE (↓ price and addition of PSS) Inj 100 mg vial – 5% DV Dec-24 to 2027	3.96	1	Solu-Cortef
78	PREDNISOLONE (addition of PSS) Oral liq 5 mg per ml – 5% DV Dec-24 to 2027	6.00	30 ml	Redipred
78	OESTRADIOL (new listing) Patch 25 mcg per day.....	18.30	8	Lyllana
	Patch 50 mcg per day.....	18.81	8	Lyllana
	Patch 75 mcg per day.....	20.84	8	Lyllana
	Patch 100 mcg per day.....	21.35	8	Lyllana
79	MEDROXYPROGESTERONE ACETATE (↑ price) Tab 2.5 mg.....	6.56	30	Provera
	Tab 5 mg.....	20.13	100	Provera
	Tab 10 mg.....	10.28	30	Provera
79	MEDROXYPROGESTERONE (↑ price) Tab 100 mg.....	133.57	100	Provera HD

INFECTIONS

86	AMIKACIN (↓ price and addition of PSS) → Inj 250 mg per ml, 2 ml vial – 5% DV Dec-24 to 2027	169.97	5	DBL Amikacin
86	TOBRAMYCIN (↓ price and addition of PSS) → Inj 40 mg per ml, 2 ml vial – 5% DV Dec-24 to 2027	15.50	5	Tobramycin (Viatriis)
87	CEFEPIME (new listing and addition of PSS) → Inj 1 g vial – 5% DV Dec-24 to 2027	3.19	1	Cefepime-AFT
	→ Inj 2 g vial – 5% DV Dec-24 to 2027	4.99	1	Cefepime-AFT
	Note – Cefepime Kabi inj 1 g vial and 2 g vial to be delisted from 1 December 2024			
90	AMOXICILLIN WITH CLAVULANIC ACID (↑ price) Grans for oral liq 25 mg with clavulanic acid 6.25 mg per ml.....	8.50	100 ml	Augmentin
90	AMOXICILLIN WITH CLAVULANIC ACID (new listing) Inj 1,000 mg with clavulanic acid 200 mg vial	26.90	10	Cerobact
91	CIPROFLOXACIN (new listing and addition of PSS) → Tab 750 mg – 5% DV Dec-24 to 2026	4.80	28	Ipca-Ciprofloxacin
	Note – Cipflox tab 750 mg to be delisted from 1 December 2024			
92	CLINDAMYCIN (↓ price and addition of PSS) → Cap 150 mg – 5% DV Dec-24 to 2027	4.94	24	Dalacin C
93	SULFADIAZINE SODIUM (new example brand listing) → Tab 500 mg			<i>e.g. Sulfadiazine-Heyl; Wockhardt</i>

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2024 (continued)

93	LINEZOLID (↓ price and addition of PSS) → Tab 600 mg – 5% DV Dec-24 to 2027	194.60	10	Zyvox
93	LINEZOLID (addition of PSS) → Inj 2 mg per ml, 300 ml bottle – 5% DV Dec-24 to 2027	155.00	10	Linezolid Kabi
93	NITROFURANTOIN (addition of PSS) Tab 50 mg – 5% DV Dec-24 to 2027	22.20	100	Nifuran
93	TRIMETHOPRIM WITH SULPHAMETHOXAZOLE [CO-TRIMOXAZOLE] (↑ price) Oral liq 8 mg with sulphamethoxazole 40 mg per ml	5.00	100 ml	Deprim
96	BEDAQUILINE (revoke delisting) → Tab 100 mg	24,162.00	188	Sirturo
	Note – Sirturo tab 100 mg, 188 tab pack to delisted from 1 July 2024			
98	MEBENDAZOLE (↓ price and addition of PSS) Tab 100 mg – 5% DV Dec-24 to 2027	5.18	6	Vermox
100	ABACAVIR SULPHATE (new listing) → Oral liq 20 mg per ml			

MUSCULOSKELETAL SYSTEM

113	BACLOFEN (↓ price and addition of PSS) Tab 10 mg – 5% DV Dec-24 to 2027	3.70	100	Pacifen
114	SUGAMMADEX (↓ price and addition of PSS) → Inj 100 mg per ml, 2 ml vial – 5% DV Dec-24 to 2027	80.64	10	Sugammadex BNM
	→ Inj 100 mg per ml, 5 ml vial – 5% DV Dec-24 to 2027	201.60	10	Sugammadex BNM
115	PARECOXIB (↓ price and addition of PSS) Inj 40 mg vial – 5% DV Dec-24 to 2027	46.00	10	Dynastat

NERVOUS SYSTEM

117	KETAMINE (↑ price) Inj 100 mg per ml, 2 ml vial	36.23	5	Ketalar
121	FENTANYL (↓ price and addition of PSS) Patch 12.5 mcg per hour – 5% DV Dec-24 to 2027	6.02	5	Fentanyl Sandoz
	Patch 25 mcg per hour – 5% DV Dec-24 to 2027	6.91	5	Fentanyl Sandoz
	Patch 50 mcg per hour – 5% DV Dec-24 to 2027	9.28	5	Fentanyl Sandoz
	Patch 75 mcg per hour – 5% DV Dec-24 to 2027	15.50	5	Fentanyl Sandoz
	Patch 100 mcg per hour – 5% DV Dec-24 to 2027	16.37	5	Fentanyl Sandoz

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2024 (continued)

122	OXYCODONE HYDROCHLORIDE (↓ price and addition of PSS)			
	Tab controlled-release 5 mg – 5% DV Dec-24 to 2027	2.49	20	Oxycodone Sandoz
	Tab controlled-release 10 mg – 5% DV Dec-24 to 2027	2.49	20	Oxycodone Sandoz
	Tab controlled-release 20 mg – 5% DV Dec-24 to 2027	3.41	20	Oxycodone Sandoz
	Inj 10 mg per ml, 1 ml ampoule – 5% DV Dec-24 to 2027	4.37	5	Hameln
	Inj 10 mg per ml, 2 ml ampoule – 5% DV Dec-24 to 2027	8.62	5	Hameln
	Inj 50 mg per ml, 1 ml ampoule – 5% DV Dec-24 to 2027	14.90	5	Hameln
122	OXYCODONE HYDROCHLORIDE (new listing)			
	Tab immediate-release 5 mg.....	13.77	100	Oxycodone Amneal
	Tab immediate-release 10 mg.....	18.77	100	Oxycodone Amneal
	Tab immediate-release 20 mg.....	26.77	100	Oxycodone Amneal
122	OXYCODONE HYDROCHLORIDE (↑ price and addition of PSS)			
	Tab controlled-release 40 mg – 5% DV Dec-24 to 2027	6.67	20	Oxycodone Sandoz
122	OXYCODONE HYDROCHLORIDE (addition of PSS)			
	Tab controlled-release 80 mg – 5% DV Dec-24 to 2027	12.99	20	Oxycodone Sandoz
125	CARBAMAZEPINE (new listing)			
	Tab 200 mg.....	14.53	100	Tegretol AU
130	AMISULPRIDE (↓ price and addition of PSS)			
	Tab 100 mg – 5% DV Dec-24 to 2027	5.84	30	Sulprix
	Tab 200 mg – 5% DV Dec-24 to 2027	14.47	60	Sulprix
	Tab 400 mg – 5% DV Dec-24 to 2027	35.06	60	Sulprix
131	ARIPIPIRAZOLE (new listing)			
	→ Inj 300 mg vial.....	273.56	1	Abilify Maintena
	→ Inj 400 mg vial.....	341.96	1	Abilify Maintena
	Note – new Pharmacode listings, 2680394 and 2680408 respectively			
131	OLANZAPINE (delay delisting date)			
	Tab 2.5 mg – 5% DV Aug-24 to 2026	1.35	28	Zypine
	Tab 5 mg – 5% DV Aug-24 to 2026	1.58	28	Zypine
	Tab 10 mg – 5% DV Aug-24 to 2026	2.01	28	Zypine
	Note – Zypine tab 2.5 mg, 5 mg and 10 mg, 28 tab pack to be delisted from 1 January 2025 August 2024			
133	BUSPIRONE HYDROCHLORIDE (↓ price and addition of PSS)			
	Tab 5 mg – 5% DV Dec-24 to 2027	13.95	100	Buspirone Viatriis
133	BUSPIRONE HYDROCHLORIDE (addition of PSS)			
	Tab 10 mg – 5% DV Dec-24 to 2027	12.50	100	Buspirone Viatriis
137	MELATONIN (↓ price and addition of PSS)			
	→ Tab modified-release 2 mg – 5% DV Dec-24 to 2027	5.80	30	Vigisom

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2024 (continued)

142	NICOTINE (↑ price)			
	Patch 7 mg per 24 hours	19.62	28	Habitrol
	Patch 14 mg per 24 hours	21.57	28	Habitrol
	Patch 21 mg per 24 hours	24.72	28	Habitrol
	Lozenge 1 mg.....	22.53	216	Habitrol
	Lozenge 2 mg.....	24.68	216	Habitrol
	Gum 2 mg	23.02	204	Habitrol (Fruit)
				Habitrol (Mint)
	Gum 4 mg	25.98	204	Habitrol (Fruit)
				Habitrol (Mint)

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

145	LOMUSTINE (new listing)			
	Cap 40 mg	880.00	20	Medac
145	CYCLOPHOSPHAMIDE (addition of PSS)			
	Tab 50 mg – 5% DV Dec-24 to 2027	145.00	50	Cyclonex
146	DAUNORUBICIN (delisting)			
	Inj 20 mg vial.....	1,495.00	10	Daunorubicin Zentiva
	Note – Daunorubicin Zentiva inj 20 mg vial to be delisted from 1 July 2024			
147	FLUOROURACIL (addition of PSS)			
	Inj 50 mg per ml, 20 ml vial – 5% DV Dec-24 to 2027	10.51	1	Fluorouracil Accord
147	FLUOROURACIL (↓ price and addition of PSS)			
	Inj 50 mg per ml, 100 ml vial – 5% DV Dec-24 to 2027	19.36	1	Fluorouracil Accord
147	MERCAPTOPYRINE (new listing)			
	→ Oral suspension 20 mg per ml	428.00	100 ml	Xaluprine
147	METHOTREXATE (↓ price and addition of PSS)			
	Tab 2.5 mg – 5% DV Dec-24 to 2027	7.80	90	Trexate
	Tab 10 mg – 5% DV Dec-24 to 2027	26.40	90	Trexate
154	CARBOPLATIN (new listing and addition of PSS)			
	Inj 10 mg per ml, 45 ml vial – 5% DV Dec-24 to 2027	25.73	1	Carboplatin Accord
	Note – Carboplatin Ebewe inj 10 mg per ml, 45 ml vial to be delisted from 1 December 2024			
154	CISPLATIN (new listing and addition of PSS)			
	Inj 1 mg per ml, 100 ml vial – 5% DV Dec-24 to 2027	18.90	1	Cisplatin Accord
	Note – DBL Cisplatin inj 1 mg per ml, 100 ml vial to be delisted from 1 December 2024			

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2024 (continued)

157	MIDOSTAURIN (new listing) → Cap 25 mg	10,981.00	56	Rydapt
	Restricted Initiation All of the following: 1 Patient has a diagnosis of acute myeloid leukaemia; and 2 Condition must be FMS tyrosine kinase 3 (FLT3) mutation positive; and 3 Patient must not have received a prior line of intensive chemotherapy for acute myeloid leukaemia; and 4 Patient is to receive standard intensive chemotherapy in combination with midostaurin only; and 5 Midostaurin to be funded for a maximum of 4 cycles.			
158	PALBOCICLIB (amended restriction criteria) → Tab 75 mg..... → Tab 100 mg..... → Tab 125 mg.....	4,000.00 4,000.00 4,000.00	21 21 21	Ibrance Ibrance Ibrance
	Restricted Initiation Medical oncologist <i>Re-assessment required after 6 months</i> Either: 1 All of the following: 1.1 1 -Patient has unresectable locally advanced or metastatic breast cancer; and 1.2 2 -There is documentation confirming disease is hormone-receptor positive and HER2-negative; and 1.3 3 -Patient has an ECOG performance score of 0-2; and 1.4 4 Either: second or subsequent line setting 1.4.1 4 -Disease has relapsed or progressed during prior endocrine therapy); or 1.4.2 4 -2-Both: first line setting 1.4.2.1 4 -2-1-Patient is amenorrhoeic, either naturally or induced, with endocrine levels consistent with a postmenopausal or without menstrual-potential state; and 1.4.2.2 4 -2-2-Patient has not received prior systemic endocrine treatment for metastatic disease 4.2.2 Either: 4.2.2.1 Patient has not received prior systemic treatment for metastatic disease; or 4.2.2.2 All of the following: 4.2.2.2.1 Patient commenced treatment with palbociclib in combination with an endocrine agent prior to 1 April 2020; and 4.2.2.2.2 Patient has not received prior systemic endocrine treatment for metastatic disease; and 4.2.2.2.3 There is no evidence of progressive disease; and 1.5 5 Treatment must be used in combination with an endocrine partner; and 1.6 Patient has not received prior funded treatment with a CDK4/6 inhibitor; or 2 All of the following: 2.1 Patient has an active Special Authority approval for ribociclib; and 2.2 Patient has experienced a grade 3 or 4 adverse reaction to ribociclib that cannot be managed by dose reductions and requires treatment discontinuation; and 2.3 Treatment must be used in combination with an endocrine partner; and 2.4 There is no evidence of progressive disease since initiation of ribociclib.			

continued...

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2024 (continued)

continued...

Continuation

~~Medical oncologist~~

~~Re-assessment required after 12 months~~

~~Both All of the following:~~

- ~~1 Treatment must be used in combination with an endocrine partner; and~~
- ~~2 No evidence of progressive disease since initiation of palbociclib; and~~
- ~~3 The treatment remains appropriate and the patient is benefitting from treatment.~~

159	RIBOCICLIB (new listing)			
	→ Tab 200 mg.....	1,883.00	21	Kisqali
		3,767.00	42	Kisqali
		5,650.00	63	Kisqali

Restricted

Initiation

~~Reassessment required after 6 months~~

Either:

1 All of the following:

- 1.1 Patient has unresectable locally advanced or metastatic breast cancer; and
- 1.2 There is documentation confirming disease is hormone-receptor positive and HER2-negative; and
- 1.3 Patient has an ECOG performance score of 0-2; and
- 1.4 Any of the following:

1.4.1 Disease has relapsed or progressed during prior endocrine therapy; or

1.4.2 Both:

1.4.2.1 Patient is amenorrhoeic, either naturally or induced, with endocrine levels consistent with a postmenopausal or without menstrual-potential state; and

1.4.2.2 Patient has not received prior systemic endocrine treatment for metastatic disease; or

1.4.3 Both

1.4.3.1 Patient commenced treatment with ribociclib in combination with an endocrine partner prior to 1 July 2024; and

1.4.3.2 There is no evidence of progressive disease; and

1.5 Treatment must be used in combination with an endocrine partner; and

1.6 Patient has not received prior funded treatment with a CDK4/6 inhibitor; or

2 All of the following:

2.1 Patient has an active Special Authority approval for palbociclib; and

2.2 Patient has experienced a grade 3 or 4 adverse reaction to palbociclib that cannot be managed by dose reductions and requires treatment discontinuation; and

2.3 Treatment must be used in combination with an endocrine partner; and

2.4 There is no evidence of progressive disease since initiation of palbociclib.

Continuation

~~Reassessment required after 12 months~~

Both:

- 1 Treatment to be used in combination with an endocrine partner; and
- 2 There is no evidence of progressive disease since initiation of ribociclib.

164	OCTREOTIDE (new listing and addition of PSS)			
	→ Inj depot 10 mg prefilled syringe – 5% DV Dec-24 to 2027 ...	438.40	1	Sandostatin LAR
	→ Inj depot 20 mg prefilled syringe – 5% DV Dec-24 to 2027 ...	583.70	1	Sandostatin LAR
	Note – Octreotide Depot Teva inj depot 10 mg prefilled syringe and 20 mg prefilled syringe to be delisted from 1 December 2024			

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2024 (continued)

164	OCTREOTIDE (addition of PSS) → Inj depot 30 mg prefilled syringe – 5% DV Dec-24 to 2027 ...	670.80	1	Sandostatin LAR
165	LETROZOLE (↓ price and addition of PSS) Tab 2.5 mg – 5% DV Dec-24 to 2027	4.67	30	Letrole
183	ADALIMUMAB (HUMIRA - ALTERNATIVE BRAND) (new listing) → Inj 40 mg per 0.4 ml prefilled pen..... Note – new Pharmacode listing, 2635003	1,599.96	2	HumiraPen

RESPIRATORY SYSTEM AND ALLERGIES

243	IPRATROPIUM BROMIDE (new listing) Nebuliser soln 250 mcg per ml, 2 ml ampoule.....	11.73	20	Ipratropium IVAX
244	SALBUTAMOL WITH IPRATROPIUM BROMIDE (new listing) Nebuliser soln 2.5 mg with ipratropium bromide 0.5 mg per 2.5 ml	11.04	20	Duolin Cipla
246	SALBUTAMOL (↑ price) Aerosol inhaler, 100 mcg per dose.....	6.80	200 dose	Ventolin

SENSORY ORGANS

252	PREDNISOLONE SODIUM PHOSPHATE (↑ price) Eye drops 0.5%, single dose (preservative free)	43.26	20 dose	Minims Prednisolone
255	BRINZOLAMIDE (↓ price and addition of PSS) Eye drops 1% – 5% DV Dec-24 to 2027	5.11	5 ml	Azopt
256	TRAVOPROST (↓ price and addition of PSS) Eye drops 0.004% – 5% DV Dec-24 to 2027	6.80	2.5 ml	Travatan
256	BRIMONIDINE TARTRATE WITH TIMOLOL MALEATE (amended chemical name, new listing and addition of PSS) Eye drops 0.2% with timolol 0.5% – 5% DV Dec-24 to 2027	7.13	5 ml	Combigan

VARIOUS

257	SODIUM HYALURONATE [HYALURONIC ACID] (↓ price and addition of PSS) Eye drops 1 mg per ml – 5% DV Dec-24 to 2027	13.58	10 ml	Hyl-Fresh
258	FLUMAZENIL (new listing and addition of PSS) Inj 0.1 mg per ml, 5 ml ampoule – 5% DV Dec-24 to 2027	44.00	5	Flumazenil-Baxter
	Note – Hameln inj 0.1 mg per ml, 5 ml ampoule to be delisted from 1 December 2024			

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2024 (continued)

SPECIAL FOODS

274	GLYCOMACROPEPTIDE AND AMINO ACID CONTAINS SOME PHENYLALANINE (amended presentation description)			
	→ Powder (Neutral), 10 g protein, 0.5 g carbohydrate, 0.6 g fat per 15 16 g sachet.....	449.28	30	PKU Build 10
	→ Powder 20 g protein, 1.7 g carbohydrate per 31 32 g sachet.....	898.56	30	PKU Build 20 Raspberry Lemonade PKU Build 20 Smooth
	→ Powder 20 g protein, 1.7 g carbohydrate per 33 32 g sachet.....	898.56	30	PKU Build 20 Vanilla
	→ Liquid (original neutral), 15 g protein, 22 g carbohydrate, 5.3 g fat per 250 ml, carton.....	684.45	30	PKU Glytactin RTD 15
274	GLYCOMACROPEPTIDE AND AMINO ACID CONTAINS SOME PHENYLALANINE (amended brand name)			
	→ Powder (neutral), 15 g protein, 15 g carbohydrate, 4.5 g fat per 40 g sachet	673.92	30	Glytactin Gamino-Pre Bettermilk
276	DIABETIC ORAL FEED 1 KCAL/ML (new listing)			
	→ Liquid 4.9 g protein, 11.7 g carbohydrate, 3.8 g fat and 2 g fibre per 100 ml, 200 ml bottle.....	2.25	200 ml	Diasip (strawberry) Diasip (vanilla)
286	ORAL FEED 1.5 KCAL/ML (new listing)			
	→ Liquid 6 g protein, 18.4 g carbohydrate and 5.8 g fat per 100 ml, 200 ml bottle.....	1.76	200 ml	Fortisip (banana) Fortisip (chocolate) Fortisip (starwberry) Fortisip (vanilla)
286	ORAL FEED WITH FIBRE 1.5 KCAL/ML (new listing)			
	→ Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 2.3 g fibre per 100 ml, 200 ml bottle	1.76	200 ml	Fortisip Multi Fibre (chocolate) Fortisip Multi Fibre (strawberry) Fortisip Multi Fibre (vanilla)

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2024 (continued)

VACCINES

287	DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE (addition of PSS) → Inj 30 IU diphtheria toxoid with 30IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin and 80 D-antigen units poliomyelitis virus in 0.5 ml syringe – 5% DV Dec-24 to 2027	0.00	10	Infanrix IPV
287	DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B AND HAEMOPHILUS INFLUENZAE TYPE B VACCINE (amended presentation description and addition of PSS) → Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin, 80 D-antigen units poliomyelitis virus, 10 mcg hepatitis B Inj 30IU diphtheria with 40IU tetanus and 25mcg pertussis toxoids, 25mcg pertussis filamentous haemagglutinin, 8mcg pertactin, 80D-AgU polio virus, 10mcg hepatitis B antigen, 10mcg H. influenzae type b with tetanus toxoid 20-40mcg in 0.5 ml syringe – 5% DV Dec-24 to 2027	0.00	10	Infanrix-hexa
287	BACILLUS CALMETTE-GUERIN VACCINE (amended brand name and addition of PSS) → Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin), Danish strain 1331, live attenuated, vial with diluent – 5% DV Dec-24 to 2027	0.00	10	BCG Vaccine AJV
288	DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE (amended presentation description and addition of PSS) → Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5 mcg pertactin in 0.5 ml prefilled syringe – 5% DV Dec-24 to 2027	0.00	10	Boostrix
288	HAEMOPHILUS INFLUENZAE TYPE B VACCINE (new listing and addition of PSS) → Inj 10 mcg vial with diluent syringe – 5% DV Dec-24 to 2027 Note – Hiberix to be delisted from 1 December 2024	0.00	10	Act-HIB
288	MENINGOCOCCAL (A, C, Y AND W-135) CONJUGATE VACCINE (addition of PSS) → Inj 10 mcg of each meningococcal polysaccharide conjugated to a total of approximately 55 mcg of tetanus toxoid carrier per 0.5 ml vial – 5% DV Dec-24 to 2027	0.00	1	MenQuadfi

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2024 (continued)

288	MENINGOCOCCAL (A, C, Y AND W-135) CONJUGATE VACCINE (new listing) → Inj 5 mcg of each meningococcal polysaccharide conjugated to a total of approximately 44 mcg of tetanus toxoid carrier per 0.5 ml vial	0.00	1	Nimenrix
	Restricted Initiation – Children under 12 months of age Any of the following: 1 A maximum of three doses (dependant on age at first dose) for patients pre- and post- splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre- or post- solid organ transplant; or 2 A maximum of three doses (dependant on age at first dose) for close contacts of meningococcal cases of any group; or 3 A maximum of three doses (dependant on age at first dose) for child who has previously had meningococcal disease of any group; or 4 A maximum of three doses (dependant on age at first dose) for bone marrow transplant patients; or 5 A maximum of three doses (dependant on age at first dose) for child pre- and post-immunosuppression*. Note: infants from 6 weeks to less than 6 months of age require a 2+1 schedule, infants from 6 months to less than 12 months of age require a 1+1 schedule. Refer to the Immunisation Handbook for recommended booster schedules with meningococcal ACWY vaccine. Note: infants from 6 weeks to less than 6 months of age require a 2+1 schedule, infants from 6 months to less than 12 months of age require a 1+1 schedule. Refer to the Immunisation Handbook for recommended booster schedules with meningococcal ACWY vaccine. *Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.			
289	MENINGOCOCCAL C CONJUGATE VACCINE (delisting) → Inj 10 mcg in 0.5 ml syringe	0.00	1	Neisvac-C
	Note – Neisvac-C inj 10 mcg in 0.5 ml syringe to be delisted from 1 December 2024			
290	PNEUMOCOCCAL (PCV13) CONJUGATE VACCINE (addition of PSS) → Inj 30.8 mcg of pneumococcal polysaccharide serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in 0.5 ml syringe – 5% DV Dec-24 to 2027	0.00	1 10	Prevenar 13 Prevenar 13
291	PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE (addition of PSS) → Inj 575 mcg in 0.5 ml pre-filled syringe (25 mcg of each 23 pneumococcal serotype) – 5% DV Dec-24 to 2027	0.00	1	Pneumovax 23

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2024 (continued)

292	COVID-19 VACCINE (new listing)			
	→ Inj 3 mcg raxtozinameran per 0.2 ml, 0.4 ml vial; infant vaccine, maroon cap	0.00	10	Comirnaty Omicron (XBB.1.5)
	Initiation – initial dose			
	Up to three doses for previously unvaccinated children aged 6 months – 4 years at high risk of severe disease.			
	→ Inj 10 mcg raxtozinameran per 0.3 ml, 0.48 ml vial; paediatric vaccine, light blue cap	0.00	10	Comirnaty Omicron (XBB.1.5)
	Initiation – initial dose			
	Either:			
	1 One dose for previously unvaccinated children aged 5-11 years old; or			
	2 Up to three doses for immunocompromised children aged 5-11 years old.			
	→ Inj 30 mcg raxtozinameran per 0.3 ml, 0.48 ml vial; adult vaccine, light grey cap	0.00	10	Comirnaty Omicron (XBB.1.5)
	Initiation – initial dose			
	Any of the following:			
	1 One dose for previously unvaccinated people aged 12-15 years old; or			
	2 Up to three doses immunocompromised people aged 12-15 years old; or			
	3 Up to two doses for previously unvaccinated people 16-29 years old; or			
	4 Up to four doses for people aged 16-29 at high risk of severe illness; or			
	5 One dose for previously unvaccinated people aged 30 and older; or			
	Initiation – additional dose			
	One additional dose every 6 months people aged 30 years and over, additional dose is given at least 6 months after last dose.			
	Continuation – additional dose			
	One additional dose every 6 months people aged 30 years and over, additional dose is given at least 6 months after last dose.			
	→ Inj 30 mcg raxtozinameran per 0.3 ml, 2.25 ml vial; adult vaccine, dark grey cap	0.00	10	Comirnaty Omicron (XBB.1.5)
	Restricted			
	Initiation – initial dose			
	Any of the following:			
	1 One dose for previously unvaccinated people aged 12-15 years old; or			
	2 Up to three doses immunocompromised people aged 12-15 years old; or			
	3 Up to two doses for previously unvaccinated people 16-29 years old; or			
	4 Up to four doses for people aged 16-29 at high risk of severe illness; or			
	5 One dose for previously unvaccinated people aged 30 and older; or			
	Initiation – additional dose			
	One additional dose every 6 months people aged 30 years and over, additional dose is given at least 6 months after last dose.			
	Continuation – additional dose			
	One additional dose every 6 months people aged 30 years and over, additional dose is given at least 6 months after last dose.			

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2024 (continued)

292	HEPATITIS A VACCINE (amended brand name and addition of PSS) → Inj 720 ELISA units in 0.5 ml syringe – 5% DV Dec-24 to 2027.....	0.00	1	Havrix Junior
	→ Inj 1440 ELISA units in 1 ml syringe – 5% DV Dec-24 to 2027.....	0.00	1	Havrix 1440
292	HEPATITIS B RECOMBINANT VACCINE (addition of PSS) → Inj 10 mcg per 0.5 ml prefilled syringe – 5% DV Dec-24 to 2027.....	0.00	1	Engerix-B
	→ Inj 20 mcg per 1 ml prefilled syringe – 5% DV Dec-24 to 2027.....	0.00	1	Engerix-B
292	HUMAN PAPILLOMAVIRUS (6, 11, 16, 18, 31, 33, 45, 52 AND 58) VACCINE [HPV] (amended restriction criteria and addition of PSS) → Inj 270 mcg in 0.5 ml syringe – 5% DV Dec-24 to 2027	0.00	10	Gardasil 9
	Initiation – Children aged 14 years and under <i>Therapy limited to 2 doses</i> Children aged 14 years and under. Initiation – other conditions Either: 1 Up to 3 doses for people aged 15 to 26 years inclusive; or 2 Both: 2.1 People aged 9 to 26 years inclusive; and 2.2 Any of the following: 2.2.1 Up to 3 doses for confirmed HIV infection; or 2.2.2 Up to 3 doses for people with a transplant (including stem cell) patients ; or 2.2.3 Up to 4 doses for Post chemotherapy. Initiation – Recurrent Respiratory Papillomatosis All of the following: 1 Either: 1.1 Maximum of two doses for children aged 14 years and under; or 1.2 Maximum of three doses for people aged 15 years and over; and 2 The person patient has recurrent respiratory papillomatosis; and 3 The person patient has not previously had an HPV vaccine.			
294	MEASLES, MUMPS AND RUBELLA VACCINE (addition of PSS) → Injection, measles virus 1,000 CCID50, mumps virus 5,012 CCID50, Rubella virus 1,000 CCID50; prefilled syringe/ampoule of diluent 0.5 ml – 5% DV Dec-24 to 2027.....	0.00	10	Priorix
294	POLIOMYELITIS VACCINE (addition of PSS) → Inj 80 D-antigen units in 0.5 ml syringe – 5% DV Dec-24 to 2027.....	0.00	1	IPOL
295	ROTAVIRUS ORAL VACCINE (addition of PSS) → Oral susp live attenuated human rotavirus 1,000,000 CCID50 per dose, prefilled oral applicator – 5% DV Dec-24 to 2027.....	0.00	10	Rotarix

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2024 (continued)

295 VARICELLA VACCINE [CHICKENPOX VACCINE] (new listing and addition of PSS)

→ Inj 2000 PFU prefilled syringe plus vial

– 5% DV Dec-24 to 2027 0.00 10 **Varilrix**

Initiation – primary vaccinations

Therapy limited to 1 dose

Either:

- 1 Any infant born on or after 1 April 2016; or
- 2 For previously unvaccinated children turning 11 years old on or after 1 July 2017, who have not previously had a varicella infection (chickenpox).

Initiation – other conditions

Therapy limited to 2 doses

Any of the following:

- 1 Any of the following:
 - for non-immune patients:
 - 1 With chronic liver disease who may in future be candidates for transplantation; or
 - 2 With deteriorating renal function before transplantation; or
 - 3 Prior to solid organ transplant; or
 - 4 Prior to any elective immunosuppression*; or
 - 5 For post exposure prophylaxis who are immune competent inpatients; or
 - 2 For patients at least 2 years after bone marrow transplantation, on advice of their specialist; or
 - 3 For patients at least 6 months after completion of chemotherapy, on advice of their specialist; or
 - 4 For HIV positive patients non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist; or
 - 5 For patients with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella; or
 - 6 For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella; or
 - 7 For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.

Note: * immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days

Note – Varivax inj 1350 PFU prefilled syringe, 1 inj and 10 inj pack to be delisted from 1 December 2024.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2024 (continued)

296	VARICELLA ZOSTER VACCINE [SHINGLES VACCINE] (amended restriction criteria) → Inj 50 mcg per 0.5 ml vial plus vial.....	0.00	1	Shingrix
			10	Shingrix
	Initiation—people aged 65 years (Zostavax) Therapy limited to 1 dose One dose for all people aged 65 years: Initiation—people aged 65 years (Shingrix) Therapy limited to 2 doses Two doses for all people aged 65 years: Initiation – people aged 18 years and over (Shingrix) Therapy limited to 2 doses Any of the following: 1 Pre- and post-haematopoietic stem cell transplant or cellular therapy; or 2 Pre- or post-solid organ transplant; or 3 Haematological malignancies; or 4 People living with poorly controlled HIV infection; or 5 Planned or receiving disease modifying anti-rheumatic drugs (DMARDs – targeted synthetic, biologic, or conventional synthetic) for polymyalgia rheumatica, systemic lupus erythematosus or rheumatoid arthritis; or 6 End stage kidney disease (CKD 4 or 5); or 7 Primary immunodeficiency.			
296	TUBERCULIN PPD [MANTOUX] TEST (addition of PSS) Inj 5 TU per 0.1 ml, 1 ml vial – 5% DV Dec-24 to 2027	0.00	1	Tubersol

Index

Pharmaceuticals and brands

A			
ABACAVIR SULPHATE	12	Cyclonex	14
Abilify Maintena	13	CYCLOPHOSPHAMIDE	14
Act-HIB	19	D	
ADALIMUMAB (HUMIRA - ALTERNATIVE BRAND).....	17	Daivobet	10
ADENOSINE	9	Dalacin C	11
Adenosine Baxter	9	DAUNORUBICIN	14
ADRENALINE	10	Daunorubicin Zentiva	14
Adsine	9	DBL Adrenaline	10
AMIKACIN	11	DBL Amikacin	11
AMISULPRIDE	13	Deprim	12
AMOXICILLIN WITH CLAVULANIC ACID	11	DIABETIC ORAL FEED 1 KCAL/ML.....	18
ARIPIPIRAZOLE	13	Diasip (strawberry)	18
ATORVASTATIN	10	Diasip (vanilla)	18
Augmentin	11	DIPHThERIA, TETANUS AND PERTUSSIS VACCINE.....	19
Azopt	17	DIPHThERIA, TETANUS, PERTUSSIS AND POLIO VACCINE	19
B		DIPHThERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B AND HAEMOPHILUS INFLUENZAE TYPE B VACCINE	19
BACILLUS CALMETTE-GUERIN VACCINE	19	DOBUTAMINE	10
BACLOFEN	12	Dobutamine-hameln	10
BCG Vaccine	19	Duolin Cipla	17
BCG Vaccine AJV	19	Dynastat	12
BEDAQUILINE	12	E	
BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL	10	Efudix	10
Boostrix	19	Engerix-B	22
BRIMONIDINE TARTRATE WITH TIMOLOL	17	EPLERENONE	9, 10
BRIMONIDINE TARTRATE WITH TIMOLOL MALEATE....	17	F	
BRINZOLAMIDE	17	FENTANYL	12
BUSPIRONE HYDROCHLORIDE	13	Fentanyl Sandoz	12
Buspirone Viatrix	13	Ferro-F-Tabs	9
C		FERROUS FUMARATE WITH FOLIC ACID	9
Camino Pro Bettermilk	18	FILGRASTIM	9
CARBAMAZEPINE	13	FLUMAZENIL	17
CARBOPLATIN	14	Flumazenil-Baxter	17
Carboplatin Accord	14	FLUOROURACIL	14
CEFEPIME	11	Fluorouracil Accord	14
Cefepime-AFT	11	FLUOROURACIL SODIUM	10
Cerobact	11	Fortisip (banana)	18
CHICKENPOX VACCINE	23	Fortisip (chocolate)	18
CINACALCET	10	Fortisip Multi Fibre (chocolate)	18
Cinacalcet Devatis	10	Fortisip Multi Fibre (strawberry)	18
CIPROFLOXACIN	11	Fortisip Multi Fibre (vanilla)	18
CISPLATIN	14	Fortisip (starwberry)	18
Cisplatin Accord	14	Fortisip (vanilla)	18
CLINDAMYCIN	11	G	
Combigan	17	Gardasil 9	22
Comirnaty Omicron (XBB.1.5)	21	GLYCOMACROPEPTIDE AND AMINO ACID CONTAINS SOME PHENYLALANINE.....	18
CO-TRIMOXAZOLE	12	Glytactin Bettermilk	18
Coversyl	9		
COVID-19 VACCINE	21		

Index

Pharmaceuticals and brands

H			
Habitrol.....	14	MENINGOCOCCAL C CONJUGATE VACCINE.....	20
Habitrol (Fruit).....	14	MenQuadfi.....	19
Habitrol (Mint).....	14	MERCAPTOPURINE.....	14
HAEMOPHILUS INFLUENZAE TYPE B VACCINE.....	19	METHOTREXATE.....	14
Havrix.....	22	MIDOSTAURIN.....	15
Havrix 1440.....	22	MILRINONE.....	10
Havrix Junior.....	22	Milrinone-Baxter.....	10
HEPARINISED SALINE.....	9	Minims Prednisolone.....	17
HEPARIN SODIUM.....	9	N	
HEPATITIS A VACCINE.....	22	Neisvac-C.....	20
HEPATITIS B RECOMBINANT VACCINE.....	22	NICOTINE.....	14
HPV.....	22	Nifuran.....	12
HUMAN PAPILLOMAVIRUS (6, 11, 16, 18, 31, 33, 45, 52 AND 58) VACCINE [HPV].....	22	Nimenrix.....	20
HumiraPen.....	17	NITROFURANTOIN.....	12
HYALURONIC ACID.....	17	Nivestim.....	9
HYDROCORTISONE.....	11	O	
Hylo-Fresh.....	17	OCTREOTIDE.....	16, 17
I		OESTRADIOL.....	11
Ibrance.....	15	OLANZAPINE.....	13
Infanrix-hexa.....	19	ORAL FEED 1.5 KCAL/ML.....	18
Infanrix IPV.....	19	ORAL FEED WITH FIBRE 1.5 KCAL/ML.....	18
Inspira.....	9, 10	Oratane.....	10
Ipca-Ciprofloxacin.....	11	Oxycodone Amneal.....	13
IPOL.....	22	OXYCODONE HYDROCHLORIDE.....	13
IPRATROPIUM BROMIDE.....	17	Oxycodone Sandoz.....	13
Ipratropium IVAX.....	17	P	
ISOTRETINOIN.....	10	Pacifen.....	12
K		PALBOCICLIB.....	15
Ketalar.....	12	PARECOXIB.....	12
KETAMINE.....	12	PERINDOPRIL.....	9
Kisqali.....	16	PIOGLITAZONE.....	9
L		PKU Build 10.....	18
Letrole.....	17	PKU Build 20 Raspberry Lemonade.....	18
LETROZOLE.....	17	PKU Build 20 Smooth.....	18
LINEZOLID.....	12	PKU Build 20 Vanilla.....	18
Linezolid Kabi.....	12	PKU Glytactin RTD 15.....	18
LOMUSTINE.....	14	PNEUMOCOCCAL (PCV13) CONJUGATE VACCINE.....	20
Lorstat.....	10	PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE.....	20
Lyllana.....	11	Pneumovax 23.....	20
M		POLIOMYELITIS VACCINE.....	22
MANTOUX.....	24	PREDNISOLONE.....	11
MEASLES, MUMPS AND RUBELLA VACCINE.....	22	PREDNISOLONE SODIUM PHOSPHATE.....	17
MEBENDAZOLE.....	12	Prevenar 13.....	20
MEDROXYPROGESTERONE.....	11	Priorix.....	22
MEDROXYPROGESTERONE ACETATE.....	11	Provera.....	11
MELATONIN.....	13	Provera HD.....	11
MENINGOCOCCAL (A, C, Y AND W-135) CONJUGATE VACCINE.....	19, 20	R	

Index

Pharmaceuticals and brands

RIFAXIMIN	9	Tobramycin (Viatriis).....	11
Rotarix	22	Travatan.....	17
ROTAVIRUS ORAL VACCINE	22	TRAVOPROST.....	17
Rydapt.....	15	Trexate.....	14
S		TRIMETHOPRIM WITH SULPHAMETHOXAZOLE [CO-TRIMOXAZOLE].....	12
SALBUTAMOL	17	TUBERCULIN PPD [MANTOUX] TEST	24
SALBUTAMOL WITH IPRATROPIUM BROMIDE.....	17	Tubersol	24
Sandostatin LAR	16, 17	V	
SHINGLES VACCINE.....	24	VARICELLA VACCINE [CHICKENPOX VACCINE].....	23
Shingrix	24	VARICELLA ZOSTER VACCINE [SHINGLES VACCINE]...	24
SILDENAFIL	10	Varilrix	23
Sirturo	12	Vedafil	10
SODIUM HYALURONATE [HYALURONIC ACID].....	17	Ventolin	17
Solu-Cortef	11	Vermox	12
SUGAMMADEX.....	12	Vexazone	9
Sugammadex BNM	12	Vigisom	13
Sulfadiazine-Heyl	11	X	
SULFADIAZINE SILVER.....	10	Xaluprine.....	14
SULFADIAZINE SODIUM.....	11	Xifaxan.....	9
Sulprix	13	Z	
T		ZOLEDRONIC ACID	11
Tegretol AU.....	13	Zoledronic acid Viatriis	11
TICAGRELOR.....	9	Zypine.....	13
Ticagrelor Sandoz	9	Zyvox.....	12
TOBRAMYCIN	11		

Pharmaceutical Management Agency
Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - www.pharmac.govt.nz
Email: enquiry@pharmac.govt.nz

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa [New Zealand Government](#)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

